Enterprise Value
-15.66M
Cash
17.75M
Avg Qtr Burn
-9.721M
Short % of Float
2.69%
Insider Ownership
2.36%
Institutional Own.
23.49%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + Pembrolizumab Details Solid tumor/s, Cancer, Head and neck squamous cell carcinoma, Melanoma | Phase 2 Data readout | |
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + etrumadenant + Doxil® Details Breast cancer, Triple-negative breast cancer , Cancer | Phase 2 Update | |
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + Nivolumab Details Urothelial cancer, Cancer | Phase 2 Update | |
Eganelisib (IPI-549) (PI3K-gamma inhibitor) + Nivolumab Details Solid tumor/s, Head and neck squamous cell carcinoma, Melanoma, Cancer | Phase 1b Data readout |